Hemogenyx Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Hemogenyx Pharmaceuticals has a total shareholder equity of £3.0M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £6.1M and £3.1M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£1.64m |
| Equity | UK£3.02m |
| Total liabilities | UK£3.09m |
| Total assets | UK£6.12m |
Recent financial health updates
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?
Aug 21
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?
May 04We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully
Jan 06Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?
Oct 09Recent updates
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?
Aug 21Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?
May 04We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully
Jan 06Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?
Oct 09Financial Position Analysis
Short Term Liabilities: HEMO's short term assets (£2.5M) exceed its short term liabilities (£564.3K).
Long Term Liabilities: HEMO's short term assets (£2.5M) do not cover its long term liabilities (£2.5M).
Debt to Equity History and Analysis
Debt Level: HEMO is debt free.
Reducing Debt: HEMO has no debt compared to 5 years ago when its debt to equity ratio was 415.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HEMO has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: HEMO is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 12:59 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hemogenyx Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|